Eli Lily has published its annual financial report, noting that the there was a 12% increase in revenue in the US, and 13% increase outside of the US, from sales of Taltz® ixekizumab. The annual report discloses that Eli Lily derived more than US$2.48 billion from the supply of Taltz® worldwide.

Healio reports a new article published in the Annals of the Rheumatic Diseases showed that ixekizumab demonstrated significantly greater joint and skin improvement than adalimumab among patients with psoriatic arthritis (PsA). The 52 week SPIRIT trial assessed 566 adults with PsA who had not yet been treated with a biological disease-modifying anti-rheumatic drugs.

Eli Lilly announced that the FDA has approved Taltz® (ixekizumab) for the treatment of non-radiographic axial spondyloarthritis.

Eli Lilly announced that the FDA has approved Taltz® (ixekizumab) for the treatment of paediatric patients with moderate to severe plaque psoriasis.

Eli Lilly announced that the FDA has approved Taltz® (ixekizumab) for the treatment of adults with active ankylosing spondylitis.